How much does a box of Dacomitinib cost?

Dacomitinib (Dacomitinib), as a targeted therapy drug for non-small cell lung cancer (NSCLC), is a second-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI). This drug was developed by Pfizer and was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2018.

Dacomitinib is particularly suitable for patients with metastatic NSCLC with EGFR mutations, among which common EGFR mutations include L858R mutation and Exon 19Deletion mutations. Compared with first-generation EGFR-TKIs (such as gefitinib and erlotinib), dacomitinib (dacomitinib), an irreversible tyrosine kinase inhibitor, inhibits EGFR activity for a longer period of time. Its mechanism of action is to irreversibly bind to the ATP binding site of EGFR, thereby blocking EGFR-mediated signal transduction and effectively inhibiting the proliferation and survival of tumor cells.

Currently, Dacomitinib (Dacomitinib) has been launched in China and has been included in the medical insurance catalog, and patients can purchase it in domestic hospital pharmacies. The price of the drug, which is 15 mg and 30 tablets, is about more than one thousand yuan. For specific prices and medical insurance reimbursement policies, please consult the local hospital pharmacy. In comparison, the foreign European version of Pfizer's original drug is priced at more than 20,000 yuan, which seems relatively expensive. The more economical choice in the foreign market is generic drugs from Laos. Its specifications are 45mg and 30 tablets. The price is about the same as before, three times lower than the domestic price, and the drug ingredients are basically the same as the original drugs.

ARCHER 1050Clinical trial results showed that dacomitinib (dacomitinib) was effective in prolonging progression-free survival (PFS) and overall survival (OS) showed better efficacy than gefitinib. Trial data showed that the median progression-free survival of patients using dacomitinib was 14.7 months, compared with 9.2 months in the gefitinib group. At the same time, the overall survival of patients in the dacomitinib (dacomitinib) group also improved. Although dacomitinib has some adverse effects, such as rash, diarrhea, stomatitis, and nail disease, these side effects are generally manageable, and patients can still benefit from it through dose adjustment and symptomatic treatment.